Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 2/20 | 0.47 |
| ▸ | CTSK | P43235 | 2/20 | 0.47 |
| ▸ | GAA | P10253 | 2/20 | 0.47 |
| ▸ | AAK1 | Q2M2I8 | 4/20 | 0.46 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.46 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.45 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.45 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.45 |
| ▸ | BTK | Q06187 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | CTSL | P07711 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | CA7 | P43166 | 1/20 | 0.38 |
| ▸ | MMP1 | P03956 | 1/20 | 0.38 |
| ▸ | MMP2 | P08253 | 1/20 | 0.38 |
| ▸ | MMP3 | P08254 | 1/20 | 0.38 |
| ▸ | MMP7 | P09237 | 1/20 | 0.38 |
| ▸ | MMP13 | P45452 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL844823 | 1.00 | CTSS (0.47) | CTSSCTSKGAAAAK1EPHX1 | |
| SCHEMBL127389 | 1.00 | CTSS (0.47) | CTSSCTSKGAAAAK1EPHX1 | |
| SCHEMBL22285129 | 1.00 | CTSS (0.47) | CTSSCTSKGAAAAK1EPHX1 | |
| SCHEMBL22285128 | 1.00 | CTSS (0.47) | CTSSCTSKGAAAAK1EPHX1 | |
| SCHEMBL22125910 | 1.00 | CTSS (0.47) | CTSSCTSKGAAAAK1EPHX1 | |
| SCHEMBL23005710 | 1.00 | CTSS (0.47) | CTSSCTSKGAAAAK1EPHX1 | |
| SCHEMBL29048029 | 0.98 | CTSS (0.46) | CTSSCTSKGAAAAK1EPHX1 | |
| Lithium SCHEMBL30468513 | 0.98 | CTSS (0.46) | CTSSCTSKGAAAAK1EPHX1 | |
| SCHEMBL464205 | 0.98 | AAK1 (0.47) | CTSSCTSKGAAAAK1EPHX1 | |
| SCHEMBL6820204 | 0.98 | AAK1 (0.47) | CTSSCTSKGAAAAK1EPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 181 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260137643-A1 | COMPOSITIONS AND METHODS USING AT LEAST ONE GLYCINE OR DERIVATIVE THEREOF AND/OR AT LEAST ONE N-ACETYLCYSTEINE OR DERIVATIVE THEREOF, AND AT LEAST ONE THYMOL AND/OR CARVACROL | SOC DES PRODUITS NESTLE S A (CH) | 2026-05-21 | — | — | US | claimed |
| US-12539288-B2 | Compositions and methods using at least one glycine or derivative thereof and/or at least one N-acetylcysteine or derivative thereof, and at least one thymol and/or carvacrol | SOCIETE DES PRODUITS NESTLE S.A. (CH) | 2026-02-03 | — | — | US | claimed |
| US-20250281438-A1 | COMPOSITIONS AND METHODS USING AT LEAST ONE GLYCINE OR DERIVATIVE THEREOF AND/OR AT LEAST ONE N-ACETYLCYSTEINE OR DERIVATIVE THEREOF, AND AT LEAST ONE THYMOL AND/OR CARVACROL | SOCIETE DES PRODUITS NESTLE S.A. (CH) | 2025-09-11 | — | — | US | claimed |
| EP-4440563-A1 | COMPOSITIONS AND METHODS USING AN AMINO ACID BLEND FOR PROVIDING A HEALTH BENEFIT IN AN ANIMAL | Société des Produits Nestlé S.A. (CH) | 2024-10-09 | — | — | EP | claimed |
| CN-118338897-A | Compositions and methods for providing health benefits in animals using amino acid blends | 雀巢产品有限公司 | 2024-07-12 | — | — | CN | claimed |
| US-20240100006-A1 | COMPOSITIONS AND METHODS USING AT LEAST ONE GLYCINE OR DERIVATIVE THEREOF AND AT LEAST ONE LARGE NEUTRAL AMINO ACID AND/OR CATIONIC AMINO ACID OR PRECURSOR THEREOF | SOCIETE DES PRODUITS NESTLE S.A. (CH) | 2024-03-28 | — | — | US | claimed |
| US-20240091186-A1 | COMPOSITIONS AND METHODS USING AT LEAST ONE GLYCINE OR DERIVATIVE THEREOF, AT LEAST ONE N-ACETYLCYSTEINE OR DERIVATIVE THEREOF, AND AT LEAST ONE NICOTINAMIDE RIBOSIDE OR NAD+ PRECURSOR | SOCIETE DES PRODUITS NESTLE S.A. (CH) | 2024-03-21 | — | — | US | claimed |
| EP-4262776-A1 | COMPOSITIONS AND METHODS USING AT LEAST ONE GLYCINE OR DERIVATIVE THEREOF AND/OR AT LEAST ONE N-ACETYLCYSTEINE OR DERIVATIVE THEREOF, AND AT LEAST ONE THYMOL AND/OR CARVACROL | Société des Produits Nestlé S.A. (CH) | 2023-10-25 | — | — | EP | claimed |
| EP-4259120-A1 | COMPOSITIONS AND METHODS USING AT LEAST ONE GLYCINE OR DERIVATIVE THEREOF AND AT LEAST ONE LARGE NEUTRAL AMINO ACID AND/OR CATIONIC AMINO ACID OR PRECURSOR THEREOF | Société des Produits Nestlé S.A. (CH) | 2023-10-18 | — | — | EP | claimed |
| US-11730711-B2 | Benefits of supplementation with n-acetylcysteine and glycine to improve glutathione levels | BAYLOR COLLEGE OF MEDICINE (US) | 2023-08-22 | — | — | US | claimed |
| US-20230172232-A1 | COMPOSITIONS AND METHODS USING AN AMINO ACID BLEND FOR PROVIDING A HEALTH BENEFIT IN AN ANIMAL | Société des Produits Nestlé S.A. (CH) | 2023-06-08 | — | — | US | claimed |
| WO-2023100077-A1 | COMPOSITIONS AND METHODS USING AN AMINO ACID BLEND FOR PROVIDING A HEALTH BENEFIT IN AN ANIMAL | SOCIETE DES PRODUITS NESTLE SA (CH) | 2023-06-08 | — | — | WO | claimed |
| CN-115957294-A | Beneficial effects of supplementation with N-acetylcysteine and glycine to improve glutathione levels | 贝勒医学院 | 2023-04-14 | — | — | CN | claimed |
| WO-2022128870-A1 | COMPOSITIONS AND METHODS USING AT LEAST ONE GLYCINE OR DERIVATIVE THEREOF AND/OR AT LEAST ONE N-ACETYLCYSTEINE OR DERIVATIVE THEREOF, AND AT LEAST ONE THYMOL AND/OR CARVACROL | Société des Produits Nestlé S.A. (CH) | 2022-06-23 | — | — | WO | claimed |
| WO-2022122730-A1 | COMPOSITIONS AND METHODS USING AT LEAST ONE GLYCINE OR DERIVATIVE THEREOF AND AT LEAST ONE LARGE NEUTRAL AMINO ACID AND/OR CATIONIC AMINO ACID OR PRECURSOR THEREOF | Société des Produits Nestlé S.A. (CH) | 2022-06-16 | — | — | WO | claimed |
| US-20260137643-A1 | COMPOSITIONS AND METHODS USING AT LEAST ONE GLYCINE OR DERIVATIVE THEREOF AND/OR AT LEAST ONE N-ACETYLCYSTEINE OR DERIVATIVE THEREOF, AND AT LEAST ONE THYMOL AND/OR CARVACROL | SOC DES PRODUITS NESTLE S A (CH) | 2026-05-21 | — | — | US | disclosed |
| US-20260124166-A1 | COMPOSITIONS AND METHODS USING GLYCINE TO REDUCE BIOLOGICAL AGE OF AN ADULT ANIMAL | Société des Produits Nestlé S.A. (CH) | 2026-05-07 | — | — | US | disclosed |
| EP-1272456-A1 | HYDRAZIDE AND ALKOXYAMIDE ANGIOGENESIS INHIBITORS | Abbott Laboratories (US) | 2003-01-08 | — | — | EP | disclosed |
| US-20020002152-A1 | Hydrazide and alkoxyamide angiogenesis inhibitors | ABBOTT LABORATORIES | 2002-01-03 | — | — | US | disclosed |
| WO-2001079157-A1 | HYDRAZIDE AND ALKOXYAMIDE ANGIOGENESIS INHIBITORS | ABBOTT LABORATORIES (US) | 2001-10-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260124166-A1 | COMPOSITIONS AND METHODS USING GLYCINE TO REDUCE BIOLOGICAL AGE OF AN ADULT ANIMAL | GLS, AGER, LRRK2 | CTSS 151/4885CTSK 376/4885GAA 1543/4885 |
| US-12539288-B2 | Compositions and methods using at least one glycine or derivative thereof and/or at least one N-acetylcysteine or derivative thereof, and at least one thymol and/or carvacrol | LIPC, GGT1, TGM2 | CTSS 395/4885CTSK 632/4885GAA 730/4885 |
| US-20260137643-A1 | COMPOSITIONS AND METHODS USING AT LEAST ONE GLYCINE OR DERIVATIVE THEREOF AND/OR AT LEAST ONE N-ACETYLCYSTEINE OR DERIVATIVE THEREOF, AND AT LEAST ONE THYMOL AND/OR CARVACROL | LIPC, GGT1, TGM2 | CTSS 307/4885CTSK 549/4885GAA 842/4885 |
| US-20020002152-A1 | Hydrazide and alkoxyamide angiogenesis inhibitors | METAP2, METAP1, ANPEP | CTSS 1777/4885CTSK 2334/4885GAA 2028/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.